UBS upgraded Cryoport (CYRX) to Buy from Neutral with a $10 price target UBS believes that scaling cell and gene therapy service offerings provide a credible pathway to low-double-digit-plus mid- to long-term sales growth and positive free cash flow, the analyst tells investors in a research note. Challenges like broader biopharma market weakness and headwinds in MVE are well understood, appear to be stabilizing, and provide an attractive entry point, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYRX:
- CryoPort’s Mixed Performance and Sector Uncertainties Justify Hold Rating
- CryoPort’s Stabilization Amid Market Uncertainties: A Hold Rating Analysis
- CryoPort’s Strong Performance and Strategic Positioning Earns Buy Rating from Analyst
- CryoPort Inc’s Earnings Call: Strong Growth and Optimism
- CryoPort trading resumes